European Medicines Agency Plans Major Revision of Pharmacogenomic Practice Guidelines
The European Medicines Agency (EMA) is set to revise its 2018 guideline on good pharmacogenomic practice. This update, outlined in a Concept paper by the Committee for Medicinal Products for Human Use (CHMP), aims to incorporate rapid scientific advancements and emerging regulatory considerations in the field. Pharmacogenomics studies how genetic variations influence individual responses to medicines, with the goal of improving treatment outcomes through personalized prescribing. The revision will address new sequencing technologies, analytical methods, and the interpretation of genotype–phenotype correlations, including their implications for clinical recommendations. Additionally, it will consider genetic variability across different ancestries and populations, standardize reporting and nomenclature, and integrate pharmacogenomics into clinical trial design and medicinal product development. The use of real-world data (RWD) in pharmacogenomics will also be a key focus. This comprehensive update seeks to ...